Last Updated：2025/11/25
After reviewing the clinical data, the committee concluded that rofecoxib posed an unacceptable cardiovascular risk and recommended its withdrawal from the market.
See correct answer
After reviewing the clinical data, the committee concluded that rofecoxib posed an unacceptable cardiovascular risk and recommended its withdrawal from the market.
音声機能が動作しない場合はこちらをご確認ください
Edit Histories（0）
